Health Condition 1: C719- Malignant neoplasm of brain, unspecified
Conditions
Interventions
None listed
Sponsors
Tata Memorial Hospital
Eligibility
Inclusion criteria
Inclusion criteria: 1.Age over 18 years at time of diagnosis. 2.Newly diagnosed diffuse glioma (Grade II-IV) being treated or previously treated with Radiotherapy plus concurrent Temozolomide +/- Adjuvant Temozolomide who developed no toxicity or Grade I myelotoxicity 3.Written informed consent.
Exclusion criteria
Exclusion criteria: 1.Recurrent gliomas treated with salvage systemic therapies. 2.Progression found before randomization/after Surgery. 3.Patients with previous history of myelosuppression due to any other cause.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Not ApplicableTimepoint: Not Applicable | — |
Primary
| Measure | Time frame |
|---|---|
| 1.To determine incidence of MGMT gene polymorphism in patients with GrII and above myelotoxicity (cases) and in patients with GrI or no toxicity (controls) in adult diffuse gliomas 2.To compare the incidence of presence of MGMT gene polymorphism in patients with GrIII and above toxicity and in patients with grade I or no toxicity. 3.To elucidate correlation/association/causal relationship between presence of MGMT gene polymorphism and grade III and above myelotoxicity.Timepoint: During RT with Conc TMZ and Adj TMZ | — |
Countries
India
Contacts
Public ContactDr Tejpal Gupta
Tata Memorial Hospital
Outcome results
None listed